PUMA BIOTECHNOLOGY, INC. PBYI

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Unless otherwise provided in this Annual Report, references to the "Company," "we," "us," and "our" refer to Puma Biotechnology, Inc. and our wholly owned subsidiary.

We are a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. Additionally, we have in-licensed, and are responsible for global development and commercialization of, alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on Aurora Kinase A. Prior to our licensing alisertib from a subsidiary of Takeda Pharmaceutical Company Limited ("Takeda"), alisertib was tested in over 1,300 patients who were treated across 22 company-sponsored trials resulting in a large, well-characterized clinical safety database. Based on information in this database, we believe alisertib has potential application in the treatment of a range of different cancer types, including hormone receptor-positive breast cancer, triple negative breast cancer and small cell lung cancer. We intend to pursue development of alisertib initially in small cell lung cancer and hormone receptor-positive breast cancer.

Last close 11.02 2026-10-23
Market cap $568.9M 2026-06-30 share count
52-week range 4.58 - 11.50

Valuation FY2025 figures against the last close

P/S2.5x
P/E18.1x
P/FCF13.6x
EV/EBITDA13.1x
Dividend yield—
Diluted EPS0.61

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $228.4M$230.5M$235.6M$228.0M$253.2M$225.1M$272.3M$251.0M$27.7M—
Cost of revenue $58.2M$64.4M$62.7M$55.1M$63.7M$39.4M$36.8M$34.6M$5.6M—
Gross profit $170.2M$166.1M$173.0M$172.9M$189.5M$185.7M$235.4M$216.4M$22.1M—
R&D ————$71.9M$97.7M$132.9M$164.9M$207.8M$222.8M
SG&A $70.8M$80.2M$89.9M$90.0M$116.3M$118.5M$141.6M$146.2M$106.7M$53.8M
Total operating expenses $191.1M$199.5M$203.0M$204.3M$251.9M$255.5M$311.3M$345.6M$320.1M$276.6M
Operating income $37.3M$31.0M$32.6M$23.7M$1.3M-$30.4M-$39.0M-$94.7M-$292.4M-$276.6M
Interest expense $6.6M$12.5M$13.3M$11.6M$12.8M$14.0M$15.0M$11.0M$720.0K—
Pre-tax income $35.8M$24.1M$22.7M$457.0K-$28.8M-$59.8M-$75.5M-$113.6M-$292.0M-$276.0M
Income tax $4.7M$6.2M$1.1M$455.0K$324.0K$207.0K$53.0K$17.0K$0$0
Net income $31.1M$30.3M$21.6M$2.0K$29.1M-$60.0M-$75.6M-$113.6M-$292.0M-$276.0M
EPS, basic 0.620.620.460.00-0.72-1.52-75,595.00———
EPS, diluted 0.610.620.450.00-0.72-1.52-1.95-2.99-7.85-8.29
Shares, diluted (wtd. avg.) 50.7M49.1M47.6M44.9M40.6M39.6M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $29.6M$69.2M$84.6M$76.2M$63.1M$85.3M$60.0M$108.4M$81.7M$194.5M
Short-term investments $67.9M$31.7M$11.4M$4.9M$19.0M$8.1M$51.6M$57.0M—$35.0M
Receivables $53.7M$32.0M$47.8M$40.4M$32.5M$25.5M$28.9M$20.8M$9.7M—
Inventory $5.5M$8.7M$7.1M$4.5M$7.1M$3.5M$3.2M$2.6M$2.0M—
Total current assets $162.7M$147.7M$156.2M$134.3M$140.0M$146.1M$166.3M$203.0M$106.4M$236.5M
Property, plant and equipment $187.0K$515.0K$855.0K$1.1M$1.8M$2.5M$3.3M$4.0M$4.5M$5.2M
Other intangibles $41.4M$51.1M$60.9M$70.6M$66.1M$74.1M$40.5M$44.4M$48.4M—
Total assets $216.3M$213.3M$230.5M$222.1M$226.6M$244.2M$234.9M$259.1M$165.5M$252.8M
Accounts payable $5.1M$5.5M$6.9M$6.4M$11.2M$12.1M$19.2M$20.7M$27.7M$20.0M
Short-term debt $22.5M$45.3M$34.0M$0$0$14.3M————
Total current liabilities $81.3M$96.1M$99.4M$77.5M$109.6M$114.3M$90.8M$67.1M$58.3M$37.5M
Long-term debt $0$21.7M$65.7M$98.3M$97.1M$84.0M$95.0M$151.9M$48.5M—
Total liabilities $86.0M$121.2M$177.1M$200.5M$229.0M$250.2M$217.4M$224.8M$112.2M$43.0M
Retained earnings -$1.28B-$1.31B-$1.35B-$1.37B-$1.37B-$1.34B-$1.28B-$1.20B-$1.09B-$796.5M
Total equity $130.3M$92.1M$53.4M$21.6M-$2.4M-$6.0M$17.5M$34.3M$53.3M$209.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $41.8M$38.9M$27.0M-$15.8M$20.6M$773.0K$22.4M-$24.1M-$172.5M-$141.7M
Depreciation and amortisation $400.0K$400.0K$400.0K$600.0K$700.0K$900.0K$900.0K$1.1M$1.1M—
Stock-based compensation $6.9M$8.2M$10.2M$11.8M$32.6M$36.6M$57.3M$86.9M$108.7M$117.3M
Capital expenditure $71.0K$56.0K$140.0K$0$0$46.0K$306.0K$170.0K$431.0K$4.3M
Investing cash flow -$36.2M-$20.4M-$19.1M$7.1M-$10.9M$33.4M$5.2M-$57.6M-$15.4M$142.2M
Financing cash flow -$45.2M-$33.8M$0$12.2M-$31.9M-$9.9M-$67.1M$108.5M$75.1M$162.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-013671.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M 400M Net income, FY2016: -276M Revenue, FY2017: 27.7M Gross profit, FY2017: 22.1M Net income, FY2017: -292M Revenue, FY2018: 251M Gross profit, FY2018: 216.4M Net income, FY2018: -113.6M Revenue, FY2019: 272.3M Gross profit, FY2019: 235.4M Net income, FY2019: -75.6M Revenue, FY2020: 225.1M Gross profit, FY2020: 185.7M Net income, FY2020: -60M Revenue, FY2021: 253.2M Gross profit, FY2021: 189.5M Net income, FY2021: 29.1M Revenue, FY2022: 228M Gross profit, FY2022: 172.9M Net income, FY2022: 2K Revenue, FY2023: 235.6M Gross profit, FY2023: 173M Net income, FY2023: 21.6M Revenue, FY2024: 230.5M Gross profit, FY2024: 166.1M Net income, FY2024: 30.3M Revenue, FY2025: 228.4M Gross profit, FY2025: 170.2M Net income, FY2025: 31.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $27.7M $251.0M $272.3M $225.1M $253.2M $228.0M $235.6M $230.5M $228.4M
Gross profit — $22.1M $216.4M $235.4M $185.7M $189.5M $172.9M $173.0M $166.1M $170.2M
Net income -$276.0M -$292.0M -$113.6M -$75.6M -$60.0M $29.1M $2.0K $21.6M $30.3M $31.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote Item 5.07
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Annual report filed Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%